Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 8/20 | 0.46 |
| ▸ | CNR2 | P34972 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099240 | 0.94 | TACR1 (0.46) | TACR1CNR1CNR2CA12CA1 | |
| SCHEMBL1848626 | 0.86 | CNR1 (0.50) | TACR1CNR1CNR2TP53MDM2 | |
| SCHEMBL1848297 | 0.85 | CNR1 (0.49) | TACR1CNR1CNR2 | |
| SCHEMBL5703250 | 0.83 | CNR1 (0.38) | TACR1CNR1CNR2MAPTPTGDR2 | |
| SCHEMBL2158648 | 0.81 | CNR1 (0.46) | TACR1CNR1CNR2 | |
| SCHEMBL1259435 | 0.81 | TACR1 (0.55) | TACR1CNR1CNR2CA12CA1 | |
| SCHEMBL1849351 | 0.80 | CNR1 (0.45) | TACR1CNR1CNR2 | |
| SCHEMBL1848918 | 0.80 | CNR1 (0.45) | TACR1CNR1CNR2 | |
| SCHEMBL2159791 | 0.80 | CNR1 (0.49) | TACR1CNR1CNR2CYP46A1 | |
| SCHEMBL1857735 | 0.80 | CNR1 (0.44) | TACR1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462631-B2 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | claimed |
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-11-23 | — | — | US | claimed |
| US-7462631-B2 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | disclosed |
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-11-23 | — | — | US | disclosed |
| EP-1678159-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF AS CANNABINOID CB-1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035488-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF AS CANNABINOID CB-1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | CNR1, CNR2, TPMT | TACR1 258/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.